Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 12/20 | 0.45 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKACG | P22612 | 2/20 | 0.39 |
| ▸ | PRKACB | P22694 | 2/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107383 | 0.84 | LIMK2 (0.52) | LIMK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL4299235 | 0.77 | LIMK2 (0.71) | LIMK2PRKACAPRKACGPRKACBLIMK1 | |
| SCHEMBL13696944 | 0.69 | TDP1 (0.53) | — | |
| SCHEMBL14074130 | 0.67 | LIMK2 (0.43) | LIMK2 | |
| SCHEMBL26050285 | 0.67 | NPC1 (0.49) | — | |
| SCHEMBL14295213 | 0.67 | AKT1 (0.47) | AKT3 | |
| SCHEMBL2798957 | 0.66 | KIT (0.50) | AKT3 | |
| Hydrochloric Acid SCHEMBL2794976 | 0.63 | AKT1 (0.67) | AKT3 | |
| SCHEMBL30694492 | 0.60 | CSF1R (0.57) | — | |
| SCHEMBL20069638 | 0.60 | FPR2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | LIMK2 1/4885PAK1 119/4885PDGFRB 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.